Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with interim data expected mid this year Completed a ...

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address ...

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (ENGN) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its ...

BOSTON & MONTREAL, September 30, 2025--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicine company, today announced that ...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product ...

Every investor in enGene Holdings Inc. (NASDAQ:ENGN) should be aware of the most powerful shareholder groups. With 52% stake, institutions possess the maximum shares in the company. In other words, ...

Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non ...

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer “As data from LEGEND's ...

A phase 2 trial of enGene's detalimogene voraplasmid in non-muscle invasive bladder cancer (NMIBC) has delivered a positive result, setting it on course for a filing with the FDA next year. The LEGEND ...

Program aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these products Detalimogene has already been manufactured ...

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer BOSTON & ...